Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) has announced a new development and license agreement with Rain Cage Carbon Inc to develop cutting-edge nanocarbon/fullerene-based contrast agents using Rain Cage's innovative EDEN carbon capture technology.
By utilizing nanocarbons produced by the EDEN system, Voyageur aims to create safer and more advanced contrast agents for medical imaging. The encapsulation and transportation of contrast agents within nanocarbons are expected to significantly enhance efficacy and safety for patients.
Initially, Voyageur secures the rights to develop fullerene-based imaging agents for North America, with plans for global expansion as development milestones are achieved and production capacity increases.
Voyageur's management views Rain Cage's EDEN system as a significant technological breakthrough capable of directly capturing CO2 and other oxides from industrial emissions. The system transforms these emissions into advanced engineered carbon material, which is essential for product development across various industries.
Fullerenes, one of the innovative materials produced by Rain Cage's system, possess high chemical stability and resistance to degradation, making them ideal for radiology contrast applications. Voyageur plans to leverage this nanocarbon innovation to create carbon-neutral and safer contrast agents that play a vital role in clearly delineating specific body areas during radiological examinations.
Voyageur CEO Brent Willis expressed excitement about the transformative potential of Rain Cage's fullerenes in the medical imaging market.
"This advanced technology has remarkable properties that may revolutionize the way contrast agents are currently used for medical imaging," Willis said in a statement.
"I am delighted by the execution of this agreement, which not only positions our company at the forefront of this innovative technology but also solidifies our future as a carbon neutral pharmaceutical company by utilizing EDEN technology. Through our partnership with Rain Cage, we will develop and manufacture innovative new imaging products while maintaining our unwavering dedication to protecting the environment, improving global health, and leaving a positive legacy for future generations."
The agreement also includes plans for defining a royalty structure for Rain Cage on sales of new fullerene-based drugs, establishing an equipment deployment agreement, and exploring monetization of carbon credits. Voyageur aims to meet its ESG mandates by implementing the EDEN technology and advancing its social and governance goals.
Rain Cage, a pioneering Canadian company focused on decarbonizing industries, offers a groundbreaking solution through its EDEN technology, which captures and transforms CO2 and other emissions into engineered carbon.
Voyageur, on the other hand, is developing barium and iodine Active Pharmaceutical Ingredients (API) and imaging contrast agents, aiming to become a key player in the market by vertically integrating its production processes.
Contact the author at jon.hopkins@proactiveinvestors.com